Human serum albumin (HSA) nanoparticles: Reproducibility of preparation process and kinetics of enzymatic degradation

International Journal of Pharmaceutics

Volumn 347, Issue 1-2, 2008, Pages 109-117

  Langer, K ^a   Anhorn, M G ^a   Steinhauser, I ^a   Dreis, S ^a   Celebi, D ^a   Schrickel, N ^a   Faust, S ^a   Vogel, V ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Enzymatic degradation; Human serum albumin (HSA); Nanoparticles; Particle size; Recombinant human serum albumin (rHSA)

Indexed keywords

CATHEPSIN B; DRUG CARRIER; HUMAN SERUM ALBUMIN; NANOPARTICLE; PEPSIN A; PROTEINASE; PROTEINASE K; THIOL GROUP; TRYPSIN;

ACIDITY; ALKALINITY; ARTICLE; DIMERIZATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENZYMATIC DEGRADATION; ENZYME KINETICS; GEL PERMEATION CHROMATOGRAPHY; NANOCHEMISTRY; PRIORITY JOURNAL; PROTEIN AGGREGATION; REPRODUCIBILITY; ULTRACENTRIFUGATION;

CATHEPSIN B; DRUG COMPOUNDING; ELECTROSTATICS; GLUTARAL; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; MOLECULAR WEIGHT; NANOPARTICLES; PARTICLE SIZE; PEPSIN A; PEPTIDE HYDROLASES; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; SERUM ALBUMIN; SURFACE PROPERTIES; TRYPSIN;

EID: 36549054137     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.06.028     Document Type: Article

References (19)

1. Balthasar S., Michaelis K., Dinauer N., von Briesen H., Kreuter J., and Langer K. Preparation and characterisation of antibody modified nanoparticles as drug carrier system for uptake in lymphocytes. Biomaterials 26 (2005) 2723-2732
2. Carter D.C., and Ho J.X. Structure of serum albumin. Adv. Protein Chem. 45 (1994) 153-203
3. Chuang V.T., Kragh-Hansen U., and Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm. Res. 19 (2002) 569-577
4. Coester C.J., Langer K., von Briesen H., and Kreuter J. Gelatin nanoparticles by two step desolvation-a new preparation method, surface modifications and cell uptake. J. Microencapsul. 17 (2000) 187-193
5. Couvreur P., and Vauhtier C. Nanotechnology: intelligent design to treat complex disease. Pharm. Res. 23 (2006) 1417-1450
6. Desai N., Trieu V., Yao Z., Louie L., Ci S., Yang A., Tao C., De T., Beals B., Dykes D., Noker P., Yao R., Labao E., Hawkins M., and Soon-Shiong P. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res. 12 (2006) 1317-1324
7. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., Hawkins M., and O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23 (2005) 7794-7803
8. He X.M., and Carter D.C. Atomic structure and chemistry of human serum albumin. Nature 358 (1992) 209-215
9. Kobayashi K. Summary of recombinant human serum albumin development. Biologicals 34 (2006) 55-59
10. Kreuter J. Nanoparticles as drug delivery systems. In: Nalwa H.S. (Ed). Encyclopedia of Nanoscience and Nanotechnology vol. 7 (2004), American Scientific Publishers, Stevenson Ranch, USA 161-180
11. Langer K., Balthasar S., Vogel V., Dinauer N., von Briesen H., and Schubert D. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int. J. Pharm. 257 (2003) 169-180
12. Michaelis K., Hoffmann M.M., Dreis S., Herbert E., Alyautdin R.N., Michaelis M., Kreuter J., and Langer K. Covalent linkage of apolipoprotein E to albumin nanoparticles strongly enhances drug transport into the brain. J. Pharm. Exp. Ther. 317 (2006) 1246-1253
13. Mukherjee S., Richik N.G., and Maxfield F.R. Endocytosis. Physiol. Rev. 77 (1997) 759-803
14. Müller R.H., Mäder K., and Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur. J. Pharm. Biopharm. 50 (2000) 161-177
15. Schuck P., Perugini M.A., Gonzales N.R., Howlett G.J., and Schubert D. Size-distribution analysis of proteins by analytical ultracentrifugation: strategies and application to model systems. Biophys. J. 82 (2002) 1096-1111
16. Schuck P., and Rossmanith P. Determination of the sedimentation coefficient distribution by least-squares boundary modeling. Biopolymers 54 (2000) 328-341
17. Steinhauser I., Spänkuch B., Strebhardt K., and Langer K. Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells. Biomaterials 27 (2006) 4975-4983
18. Vogel V., Langer K., Balthasar S., Schuck P., Mächtle W., Haase W., van den Broek J.A., Tziatzios C., and Schubert D. Characterization of serum albumin nanoparticles by sedimentation velocity analysis and electron microscopy. Progr. Colloid Polym. Sci. 119 (2002) 31-36
19. Wartlick H., Spänkuch-Schmitt B., Strebhardt K., Kreuter J., and Langer K. Tumour cell delivery of antisense oligonucleotides by human serum albumin nanoparticles. J. Controll. Rel. 96 (2004) 483-495